AstraZeneca plc (AZN) Insider Buys £1,704.30 in Stock
AstraZeneca plc (LON:AZN) insider Nazneen Rahman acquired 39 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($56.93) per share, for a total transaction of £1,704.30 ($2,220.30).
AstraZeneca plc (LON:AZN) traded up 2.88% during mid-day trading on Friday, hitting GBX 4449.50. 2,219,873 shares of the stock were exchanged. The company’s market cap is GBX 56.33 billion. AstraZeneca plc has a one year low of GBX 3,996.00 and a one year high of GBX 5,520.00. The company has a 50-day moving average price of GBX 5,187.89 and a 200-day moving average price of GBX 4,861.95.
The company also recently declared a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be issued a GBX 68.90 ($0.90) dividend. This represents a yield of 1.35%. The ex-dividend date of this dividend is Thursday, August 10th.
WARNING: This report was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/28/astrazeneca-plc-azn-insider-buys-1704-30-in-stock.html.
A number of brokerages recently commented on AZN. Morgan Stanley reissued an “overweight” rating and issued a GBX 5,600 ($72.95) price objective on shares of AstraZeneca plc in a research note on Friday, June 23rd. UBS AG set a GBX 5,150 ($67.09) price objective on shares of AstraZeneca plc and gave the company a “neutral” rating in a research note on Tuesday, June 27th. Shore Capital reissued a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, June 21st. Barclays PLC reissued an “overweight” rating and issued a GBX 6,000 ($78.17) price objective on shares of AstraZeneca plc in a research note on Monday, June 5th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of AstraZeneca plc in a research note on Monday, June 5th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and nine have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of GBX 5,189.30 ($67.60).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.